Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2005

01-08-2005

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

Authors: Susan M. Chang, Patrick Wen, Timothy Cloughesy, Harry Greenberg, David Schiff, Charles Conrad, Karen Fink, H. Ian Robins, Lisa De Angelis, Jeffrey Raizer, Kenneth Hess, Ken Aldape, Kathleen R. Lamborn, John Kuhn, Janet Dancey, Michael D. Prados, North American Brain Tumor Consortium and the National Cancer Institute

Published in: Investigational New Drugs | Issue 4/2005

Login to get access
Metadata
Title
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Authors
Susan M. Chang
Patrick Wen
Timothy Cloughesy
Harry Greenberg
David Schiff
Charles Conrad
Karen Fink
H. Ian Robins
Lisa De Angelis
Jeffrey Raizer
Kenneth Hess
Ken Aldape
Kathleen R. Lamborn
John Kuhn
Janet Dancey
Michael D. Prados
North American Brain Tumor Consortium and the National Cancer Institute
Publication date
01-08-2005
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 4/2005
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-005-1444-0

Other articles of this Issue 4/2005

Investigational New Drugs 4/2005 Go to the issue

OriginalPaper

Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer

OriginalPaper

Gemcitabine and mitoxantrone in metastatic breast cancer: A phase-I-study

Erratum

Phase I Study of Tomudex and Doxorubicin in Patients with Locally Advanced, Inoperable or Metastatic Cancer (IND.98)

OriginalPaper

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

OriginalPaper

Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP

OriginalPaper

Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits